Intermediate term outcomes of SIBS microshunt alone or in combination with phacoemulsification
Mon statut pour la session
Author Disclosure Block: J. Yohannan: None. H. Gulamhusein: None. M.B. Schlenker: None. I.I.K. Ahmed: Grant/research support; Name of Commercial Company(s); Allergan, Abbott Medical Optics, Bausch & Lomb, Carl Zeiss. Employment/honoraria/consulting fees; Name of Commercial Company(s); Glaukos, Ivantis, Transcent, Allergan, Neomedix.
Abstract Body:
Purpose: Evaluate intermediate term outcomes of SIBS microshunt with mitomycin C alone or in combination with phacoemulsification in glaucoma patients.
Study Design: Retrospective longitudinal case series.
Methods: 159 consecutive eyes in 143 patients with a diagnosis of glaucoma received the SIBS microshunt with mitomycin C at a single institution. Of these, 125 eyes had a standalone microshunt implantation (solo group) and 34 eyes had microshunt implantation with concurrent phacoemulsification (combo group). Primary outcome was median IOP at the last follow-up visit. Secondary outcome was the median number of glaucoma medications at the last follow up. Complications and re-operations were recorded.
Results: Median follow-up time was 12 mos (IQR 9-16 mos). Overall, median pre-operative IOP was 22 mmHg (IQR 18-28) and median number of medications was 4 (IQR 3-4). Median IOP and number of medications decreased to 13mmHg (IQR 11-17) and 0 (IQR 0-1) respectively at last follow up.
In the 125 solo eyes, median pre-operative IOP and medications were were 21 (IQR 18-28) and 4 (IQR 3-4) respectively. This decreased to 13 (IQR 11-16) and 0 (IQR 0-2) at last follow-up.
In the 34 combo eyes, median pre-operate IOP and medications were 24 (IQR 20-29) and 4 (IQR 3-4) respectively. This decreased to 14 (IQR 11-17) and 0 (IQR 0-0) at last follow-up.
Complications were transient. 2 eyes required surgical revision and 1 required tube shunt surgery.
Conclusions: These data suggest that SIBS microshunt can effectively lower IOP and reduce number of medications in patients with glaucoma. The efficacy of the device appears to be similar when used stand-alone or in combination with phacoemulsification. There were minimal complications and a low rate of repeat surgery.
